Women’s telehealth company Midi Health has introduced a new brand identity and redesigned website as it broadens its clinical offering to support women across more stages of life.
The company, which has provided care to more than 450,000 patients, is moving beyond its established focus on menopause and midlife health to introduce a broader range of services. Its expanded offering now includes care for Polyendocrine Metabolic Ovarian Syndrome (PMOS) and metabolic health, with additional areas of care expected to follow.
The new website brings these services together in one place, giving patients a clearer view of the care options available to them, from clinical laboratory services and hormone therapy to supplements.
Midi built its reputation around clinician-led care for women navigating menopause and midlife health. Its latest expansion represents a broader ambition: to become a healthcare partner for women across different stages of their lives.
Joanna Strober, CEO and co-founder of Midi Health, said the company is laying the foundation for its next era of growth by expanding into both specialised and primary care needs.
“As the lines between primary and specialty care begin to converge, we are perfectly positioned to take on both the specialized and primary care needs of our patients. We’ve earned women’s trust by delivering compassionate, effective, clinician-led care through midlife, and we’re now applying that same model to more and new clinical care types. The wider breadth of treatment options we’re rolling out are designed to provide women with the care they deserve in every life stage, and we’re honored to be their trusted care partner across many decades,” Strober said.
The company’s expanded model is intended to give women access to a wider range of treatment options while maintaining a personalised approach based on their symptoms, health needs and preferences.
Technology is also playing a growing role in Midi’s expansion.
The company has integrated AI-powered clinical tools to help its healthcare providers deliver personalised, evidence-based care more efficiently as the range of conditions it treats expands.
Midi says the technology is intended to support its clinicians rather than replace the human side of healthcare. Clinical judgement and empathy remain central to the patient experience, while AI tools help providers manage the increasing complexity and breadth of care.
The approach reflects a wider shift in healthcare towards combining advanced technology with human-led clinical decision-making.
Midi’s transformation extends beyond its clinical offering.
The company’s refreshed visual identity uses bold typography and high-contrast colour, deliberately moving away from more muted and understated aesthetics traditionally associated with women’s healthcare.
The brand change reflects Midi’s broader message that women’s health should not be treated as a niche area of healthcare.
Melissa Waters, Chief Marketing Officer of Midi Health, said women are looking for a trusted healthcare partner that can support them throughout different stages of their lives rather than addressing only a single health concern.
“It’s time to stop treating women’s health as a niche when we are half the population,” Waters said.
The expansion represents a significant shift in Midi’s positioning.
Rather than focusing on one particular stage of women’s health, the company is building towards a model that can support patients across multiple decades, combining specialised treatment with broader healthcare needs.
For patients, the redesigned platform is intended to make it easier to understand the full range of services available and develop care plans based on their individual circumstances.
With more than 450,000 patients cared for to date, Midi enters its next phase with an established patient base and a broader clinical ambition.
Its latest move signals how quickly women’s healthcare is evolving, with telehealth, AI and personalised medicine increasingly being brought together to create more continuous models of care.
